Therapeutic Targeting of Autoreactive B Cells: Why, How, and When?
B lymphocytes play critical roles in the development of autoimmunity, acting as autoantibody manufacturers, antigen-presenting cells, and producers of cytokines. Pan-B cell depletion has demonstrated efficacy in treatment of many autoimmune disorders, but carries with it an unfavorable safety profil...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/9/1/83 |
| _version_ | 1797410759115800576 |
|---|---|
| author | Zachary C. Stensland John C. Cambier Mia J. Smith |
| author_facet | Zachary C. Stensland John C. Cambier Mia J. Smith |
| author_sort | Zachary C. Stensland |
| collection | DOAJ |
| description | B lymphocytes play critical roles in the development of autoimmunity, acting as autoantibody manufacturers, antigen-presenting cells, and producers of cytokines. Pan-B cell depletion has demonstrated efficacy in treatment of many autoimmune disorders, but carries with it an unfavorable safety profile due to global immune suppression. Hence, attention has turned to the potential of autoantigen-specific B cell targeted therapies, which would deplete or silence pathogenic self-antigen-reactive cells while sparing B cells needed for immune defense. Here, we discuss the antigen-specific B cell-targeted approaches that are under development or are under consideration, that could be employed to allow for more precise therapy in the treatment of autoimmunity. Lastly, we discuss some of the challenges associated with antigen-specific B cell targeting that may impact their clinical applicability. |
| first_indexed | 2024-03-09T04:34:51Z |
| format | Article |
| id | doaj.art-5b6072cde55c49f4855d557cb46cd4e9 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-09T04:34:51Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-5b6072cde55c49f4855d557cb46cd4e92023-12-03T13:30:36ZengMDPI AGBiomedicines2227-90592021-01-01918310.3390/biomedicines9010083Therapeutic Targeting of Autoreactive B Cells: Why, How, and When?Zachary C. Stensland0John C. Cambier1Mia J. Smith2Barbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USADepartment of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO 80045, USABarbara Davis Center for Diabetes, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO 80045, USAB lymphocytes play critical roles in the development of autoimmunity, acting as autoantibody manufacturers, antigen-presenting cells, and producers of cytokines. Pan-B cell depletion has demonstrated efficacy in treatment of many autoimmune disorders, but carries with it an unfavorable safety profile due to global immune suppression. Hence, attention has turned to the potential of autoantigen-specific B cell targeted therapies, which would deplete or silence pathogenic self-antigen-reactive cells while sparing B cells needed for immune defense. Here, we discuss the antigen-specific B cell-targeted approaches that are under development or are under consideration, that could be employed to allow for more precise therapy in the treatment of autoimmunity. Lastly, we discuss some of the challenges associated with antigen-specific B cell targeting that may impact their clinical applicability.https://www.mdpi.com/2227-9059/9/1/83B cellsautoimmunityself-antigenantigen-specific therapiestoleranceB lymphocytes |
| spellingShingle | Zachary C. Stensland John C. Cambier Mia J. Smith Therapeutic Targeting of Autoreactive B Cells: Why, How, and When? Biomedicines B cells autoimmunity self-antigen antigen-specific therapies tolerance B lymphocytes |
| title | Therapeutic Targeting of Autoreactive B Cells: Why, How, and When? |
| title_full | Therapeutic Targeting of Autoreactive B Cells: Why, How, and When? |
| title_fullStr | Therapeutic Targeting of Autoreactive B Cells: Why, How, and When? |
| title_full_unstemmed | Therapeutic Targeting of Autoreactive B Cells: Why, How, and When? |
| title_short | Therapeutic Targeting of Autoreactive B Cells: Why, How, and When? |
| title_sort | therapeutic targeting of autoreactive b cells why how and when |
| topic | B cells autoimmunity self-antigen antigen-specific therapies tolerance B lymphocytes |
| url | https://www.mdpi.com/2227-9059/9/1/83 |
| work_keys_str_mv | AT zacharycstensland therapeutictargetingofautoreactivebcellswhyhowandwhen AT johnccambier therapeutictargetingofautoreactivebcellswhyhowandwhen AT miajsmith therapeutictargetingofautoreactivebcellswhyhowandwhen |